Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
What’s Behind the Strong Growth of the Hyperimmune Globulins Market Size in the Last 5 Years?
There has been a robust growth in the size of the hyperimmune globulins market in the past few years. The market is set to increase from $1.91 billion in 2024 to $2.06 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.8%.
Factors contributing to this growth during the historic period include higher government backing and an upswing in healthcare spending.
The market size for hyperimmune globulins is predicted to experience notable expansion in the upcoming years. By 2029, it is set to reach $2.76 billion, with a compound annual growth rate (CAGR) of 7.6%.
The projected growth within this period is credited to a rise in infectious diseases, increased consciousness about hyperimmune globulin injection benefits, surging demand for immunoglobulins, growing instances of alpha-1 antitrypsin deficiency, and a rise in immune deficiencies occurrences. The anticipated trends for this future period include technological progress and innovation, greater investment in research and development, the rising demand for passive immunity treatments, progress in plasma-derived therapies, and advancements in manufacturing technologies.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What Drivers Are Powering the Rise of the Hyperimmune Globulins Market?
The escalation in the instances of infectious diseases is anticipated to foster the expansion of the hyperimmune globulin market. Infectious diseases refer to ailments induced by harmful pathogens such as viruses, bacteria, fungi, and parasites entering your body.
The rising occurrences of these diseases are due to factors like antimicrobial resistance, climate change, and population increase. Hyperimmune globulins, applied in managing infectious diseases, offer immediate passive immunity by supplying concentrated antibodies against specific pathogens, thereby assisting in preventing or treating diseases like rabies, hepatitis B, or tetanus.
For example, in April 2024, the Centers for Disease Control and Prevention, a US government agency, reported that the instances of chronic hepatitis B in the US had surged by approximately 17% from 14,229 cases in 2021 to 16,729 cases in 2022.
Thus, the growing instances of infectious diseases are fueling the expansion of the hyperimmune globulin market.
Government-led research and development initiatives in healthcare are anticipated to drive the expansion of the hyperimmune globulins market. The rise in these initiatives is due to an increasing demand for ground-breaking medical solutions and the necessity to tackle emerging health-related issues.
Such initiatives promote the development and accessibility of hyperimmune globulins for effectively combating specific infectious diseases. For instance, the Department of Health and Social Care, a UK government body, in 2022 announced a funding of £260 million (US $270.65 million) aimed at boosting healthcare research and manufacturing.
This pledge was done by Business, Energy, and Industrial Strategy (BEIS) unit and the Department of Health and Social Care (DHSC) to bolster NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. At the same time, £60 million (US $63.60 million) was allocated to enhance life sciences manufacturing in the UK.
Hence, the burgeoning government initiatives in healthcare research and development are stimulating the hyperimmune globulins market.
How Is the Hyperimmune Globulins Market Structured Across Key Segments?
The hyperimmune globulins market covered in this report is segmented –
1) By Type: Hepatitis B Hyperimmune Globulin, Rabies Hyperimmune Globulin, Tetanus Hyperimmune Globulin, Cytomegalovirus (CMV) Hyperimmune Globulin, Varicella-Zoster Virus (VZV) Hyperimmune Globulin, Respiratory Syncytial Virus (RSV) Hyperimmune Globulin, Other Types
2) By Route Of Administration: Intramuscular, Intravenous
3) By Application: Government Institution, Private Sector, Other Applications
Subsegments:
1) By Hepatitis B Hyperimmune Globulin: Intramuscular Hepatitis B Hyperimmune Globulin, Intravenous Hepatitis B Hyperimmune Globulin
2) By Rabies Hyperimmune Globulin: Rabies Immune Globulin (Human), Rabies Immune Globulin (Equine)
3) By Tetanus Hyperimmune Globulin: Tetanus Immune Globulin (Human), Tetanus Immune Globulin (Equine)
4) By Cytomegalovirus (Cmv) Hyperimmune Globulin: Cmv Immune Globulin For Organ Transplantation, Cmv Immune Globulin For Neonatal Infection
5) By Varicella-Zoster Virus (Vzv) Hyperimmune Globulin: Vzv Immune Globulin For Post-Exposure Prophylaxis, Vzv Immune Globulin For Immunocompromised Patients
6) By Respiratory Syncytial Virus (Rsv) Hyperimmune Globulin: Rsv Immune Globulin For Infants And Children, Rsv Immune Globulin For Adults With Respiratory Conditions
7) By Other Types: Diphtheria Hyperimmune Globulin, Botulism Hyperimmune Globulin, Other Specialized Hyperimmune Globulins
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
How Will Market Trends Drive Strategic Shifts in the Hyperimmune Globulins Sector?
Where Is the Hyperimmune Globulins Market Experiencing the Fastest Regional Growth?
North America was the largest region in the hyperimmune globulins market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in the hyperimmune globulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
Leading Players Shaping the Future of the Hyperimmune Globulins Industry
Major companies operating in the hyperimmune globulins market are F. Hoffmann-La Roche AG, Bayer AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Ltd., Fresenius Kabi AG, Grifols SA, Octapharma AG, Shanghai RAAS Blood Products Co.
Ltd., Emergent BioSolutions Inc., Kedrion Biopharma Inc., LFB SA, Hualan Biological Engineering Inc., FFF Enterprises Inc., Taibang Biologic Group, Bio Products Laboratory (BPL) Ltd., ADMA Biologics, Cangene Corporation, Kamada Ltd., Saol Therapeutics Inc., Omrix Biopharmaceuticals Ltd., Shire, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., BioCare Inc.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=16448
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
